{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:17:17Z","timestamp":1793312237489,"version":"4.5.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Continuous low-dose 5-FU was popularized as a therapy for pretreated metastatic breast cancer for the past few decades, spurred by the advent of the electronic infusion pump. Capecitabine, otherwise known by its trade name Xeloda, is a prodrug of 5-fluorouracil (5-FU), which is administered orally in many chemotherapy regimens, and plays a role in metastatic breast cancer treatment refractory to traditional anthracyclines and taxane therapy. In this case presentation, we describe a unique case of refractory <jats:italic>de-novo<\/jats:italic> stage IV triple-negative breast cancer presented with right breast primary invasive ductal carcinoma, extensive lymphadenopathy, with biopsy proven bone marrow infiltration, diffuse hepatomegaly, splenomegaly, significant hyperbilirubinemia, and bone marrow failure treated with continuous 5-FU infusion and subsequently oral capecitabine after initial treatment failure with nab-paclitaxel and sacituzimab govitecan. With this case presentation, the authors aim to showcase the versatility of 5-FU and its prodrug in treatment of metastatic triple-negative breast cancer with severe bone marrow and liver involvement while highlighting key physiologic and pharmacologic mechanisms.<\/jats:p>","DOI":"10.3389\/fonc.2023.1305584","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:29:25Z","timestamp":1705292965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case report: An exceptional responder of low-dose continuous 5-FU in a patient with de-novo stage IV triple-negative breast cancer with liver and bone marrow failure"],"prefix":"10.3389","volume":"13","author":[{"given":"Bryan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejca.2022.05.015","article-title":"Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry","volume":"172","author":"M\u00fcller","year":"2022","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.924141","article-title":"Diffuse intrasinusoidal hepatic metastasis from breast cancer presenting as liver failure: effective and rapid treatment with weekly low-dose adriamycin","volume":"21","author":"Afiat","year":"2020","journal-title":"Am J Case Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1042773","article-title":"Symptomatic bone marrow metastases in breast cancer: A retrospective cohort study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.12264","article-title":"Prognostic evaluation of breast cancer patients with evident bone marrow metastasis","volume":"20","author":"Demir","year":"2014","journal-title":"Breast J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1538-7445.SABCS14-S3-01","article-title":"The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1\/2 breast cancer (CRUK\/07\/012)","volume":"75","author":"Tutt","year":"2015","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin oncology: Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000111479","article-title":"Five years of clinical experience with metronomic chemotherapy: achievements and perspectives","volume":"30","author":"Emmenegger","year":"2007","journal-title":"Onkologie."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3390\/jcm11164710","article-title":"Metronomic chemotherapy for metastatic breast cancer treatment: Clinical and preclinical data between lights and shadows","volume":"11","author":"Cazzaniga","year":"2022","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010759","article-title":"Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer","volume":"7","author":"Regazzoni","year":"1996","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-105871","article-title":"Metronomic chemotherapy for metastatic breast cancer\u2013a systematic review of the literature","volume":"13","author":"Banys-Paluchowski","year":"2016","journal-title":"Senologie-Zeitschrift f\u00fcr Mammadiagnostik und-therapie"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand\u2013foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug safety"},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu Rev Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1305584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:29:27Z","timestamp":1705292967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1305584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":15,"alternative-id":["10.3389\/fonc.2023.1305584"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1305584","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"article-number":"1305584"}}